By Katherine Hamilton
Kamada shares climbed after the company released its guidance for 2025 and updated its progress on a therapy trial.
The biopharmaceutical company's stock advanced 16% to $7.92. Shares have gained 30% over the past 12 months.
Kamada expects to earn $178 million to $182 million in revenue during 2025, which would be a 13% increase from the previous year. It anticipates $38 million to $42 million in adjusted EBITDA.
The company affirmed guidance for $158 million to $162 million in annual revenue in 2024. Year-end cash should be around $78 million, it said. Adjusted EBITDA is anticipated to be $32 million to $35 million.
The operational cash will provide resources for new business development and mergers and acquisitions in 2025, Chief Executive Amir London said. Kamada also plans to expand its plasma collection operations, including opening a third location in San Antonio in the first quarter of 2025.
Kamada expects to advance its phase-three trial of its Inhaled Alpha-1 Antitrypsin therapy. The FDA confirmed an agreement for the trial, which will allow Kamada to reduce the study sample size from 220 patients to 180 while maintaining statistical power. An interim futility analysis is expected to happen by the end of 2025.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 08, 2025 14:06 ET (19:06 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。